Akebia Therapeutics Inc (AKBA)
1.805
-0.06
(-2.96%)
USD |
NASDAQ |
Nov 15, 11:20
Akebia Therapeutics Free Cash Flow (Quarterly): -6.697M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -6.697M |
June 30, 2024 | -10.10M |
March 31, 2024 | -19.43M |
December 31, 2023 | -2.308M |
September 30, 2023 | -7.167M |
June 30, 2023 | 3.629M |
March 31, 2023 | -17.54M |
December 31, 2022 | -54.68M |
September 30, 2022 | 33.80M |
June 30, 2022 | -30.66M |
March 31, 2022 | -21.73M |
December 31, 2021 | -62.81M |
September 30, 2021 | -56.27M |
June 30, 2021 | -63.14M |
March 31, 2021 | -70.80M |
December 31, 2020 | -31.10M |
September 30, 2020 | -27.19M |
June 30, 2020 | 37.18M |
March 31, 2020 | -89.59M |
December 31, 2019 | -92.36M |
September 30, 2019 | 8.46M |
June 30, 2019 | -40.34M |
March 31, 2019 | -139.86M |
December 31, 2018 | -74.53M |
Date | Value |
---|---|
September 30, 2018 | -12.77M |
June 30, 2018 | 8.823M |
March 31, 2018 | -20.63M |
December 31, 2017 | -16.83M |
September 30, 2017 | -55.21M |
June 30, 2017 | 24.22M |
March 31, 2017 | -9.955M |
December 31, 2016 | 95.62M |
September 30, 2016 | -29.50M |
June 30, 2016 | -28.20M |
March 31, 2016 | 17.32M |
December 31, 2015 | -22.98M |
September 30, 2015 | -9.146M |
June 30, 2015 | -12.14M |
March 31, 2015 | -8.547M |
December 31, 2014 | -9.224M |
September 30, 2014 | -5.64M |
June 30, 2014 | -6.698M |
March 31, 2014 | -6.15M |
December 31, 2013 | -4.921M |
September 30, 2013 | -2.944M |
June 30, 2013 | -1.957M |
March 31, 2013 | -1.530M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-92.36M
Minimum
Dec 2019
37.18M
Maximum
Jun 2020
-29.45M
Average
-24.46M
Median
Free Cash Flow (Quarterly) Benchmarks
Corcept Therapeutics Inc | 72.19M |
Bioventus Inc | 10.25M |
Eli Lilly and Co | -458.90M |
NovaBay Pharmaceuticals Inc | -2.063M |
Palatin Technologies Inc | -6.477M |